中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1704-1709

Research advances in butyrogenic microbes and butyrate in the treatment of hepatocellular carcinoma

DOI: 10.12449/JCH260730
  • 1.

    School of Medicine，University of Electronic Science and Technology of China，Chengdu 610054，China

  • 2.

    Department of Hepato-Biliary-Pancreatic Surgery，Sichuan Cancer Hospital & Institute，Sichuan Clinical Research Center for Cancer，Sichuan Cancer Center，Affiliated Cancer Hospital of University of Electronic Science and Technology of China，Chengdu 610041，China

Research funding:

Project of Chengdu High-Tech Zone Medical Association (2024003)

More Information
  • Corresponding author: Wang Haiqing， wanghaiqing241286@163.com （ORCID： 0000-0003-4621-4605）
  • Received Date: 2025-10-21
  • Accepted Date: 2026-01-29
  • Published Date: 2026-07-25
    Abstract
  • Hepatocellular carcinoma （HCC） is a hepatic malignancy with a high mortality rate， and the development and progression of HCC is closely associated with gut microbiota and their metabolites. Butyrate is a kind of short-chain fatty acid produced by gut microbiota through metabolism， and it plays an important role in various aspects such as protecting intestinal barrier， regulating immune response， and exerting an antitumor effect. Notably， there is a reduction in the abundance of butyrogenic microbes and dysregulation of butyrate metabolism in patients with HCC， which provides new ideas for the treatment of HCC based on microbes and their metabolites. Current studies have preliminarily shown that butyrogenic microbes and butyrate exhibit both predictive and synergistic effects in the treatment of HCC and thus have broad prospects for clinical application. This article systematically elaborates on their characteristics in the progression of HCC， summarizes related research advances in their combination with systemic treatment strategies， and provides new insights for future research directions， in order to promote their clinical application.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    Llovet J M, Pinyol R, Kelley R K, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma[J]. Nat Cancer, 2022, 3( 4): 386- 401. DOI: 10.1038/s43018-022-00357-2.
    [2]
    Yang X P, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma[J]. Cancer Cell, 2024, 42( 2): 180- 197. DOI: 10.1016/j.ccell.2024.01.007.
    [3]
    Tilg H, Adolph T E, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34( 11): 1700- 1718. DOI: 10.1016/j.cmet.2022.09.017.
    [4]
    Cui Yan, Jiao Junzhe, Yan Ruijuan, et al. The role of gut microbiota homeostasis in the occurrence and development of hepatocellular carcinoma and targeted intervention strategies[J]. J Clin Hepatol, 2025, 41( 9): 1913- 1919. DOI: 10.12449/JCH250930.

    崔艳, 焦俊喆, 闫瑞娟, 等. 肠道菌群稳态在肝细胞癌发生发展中的作用及相关靶向干预策略[J]. 临床肝胆病杂志, 2025, 41( 9): 1913- 1919. DOI: 10.12449/JCH250930.
    [5]
    Schneider K M, Mohs A, Gui W F, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment[J]. Nat Commun, 2022, 13( 1): 3964. DOI: 10.1038/s41467-022-31312-5.
    [6]
    Mukhopadhya I, Louis P. Gut microbiota-derived short-chain fatty acids and their role in human health and disease[J]. Nat Rev Microbiol, 2025, 23( 10): 635- 651. DOI: 10.1038/s41579-025-01183-w.
    [7]
    Sun J Z, Chen S Q, Zang D, et al. Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic(Review)[J]. Int J Oncol, 2024, 64( 4): 44. DOI: 10.3892/ijo.2024.5632
    [8]
    Hodgkinson K, El Abbar F, Dobranowski P, et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease[J]. Clin Nutr, 2023, 42( 2): 61- 75. DOI: 10.1016/j.clnu.2022.10.024.
    [9]
    Singh V, Lee G, Son H, et al. Butyrate producers,“The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics[J]. Front Microbiol, 2023, 13: 1103836. DOI: 10.3389/fmicb.2022.1103836.
    [10]
    Salvi P S, Cowles R A. Butyrate and the intestinal epithelium: Modulation of proliferation and inflammation in homeostasis and disease[J]. Cells, 2021, 10( 7): 1775. DOI: 10.3390/cells10071775.
    [11]
    Gasaly N, Hermoso M A, Gotteland M. Butyrate and the fine-tuning of colonic homeostasis: Implication for inflammatory bowel diseases[J]. Int J Mol Sci, 2021, 22( 6): 3061. DOI: 10.3390/ijms22063061.
    [12]
    Pant K, Venugopal S K, Lorenzo Pisarello M J, et al. The role of gut microbiome-derived short-chain fatty acid butyrate in hepatobiliary diseases[J]. Am J Pathol, 2023, 193( 10): 1455- 1467. DOI: 10.1016/j.ajpath.2023.06.007.
    [13]
    Zheng M X, Yang X Y, Wu Q Y, et al. Butyrate attenuates hepatic steatosis induced by a high-fat and fiber-deficient diet via the hepatic GPR41/43-CaMKII/HDAC1-CREB pathway[J]. Mol Nutr Food Res, 2023, 67( 1): 2200597. DOI: 10.1002/mnfr.202200597.
    [14]
    Ren Z G, Li A, Jiang J W, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut, 2019, 68( 6): 1014- 1023. DOI: 10.1136/gutjnl-2017-315084.
    [15]
    Huo R, Chen Y L, Li J, et al. Altered gut microbiota composition and its potential association in patients with advanced hepatocellular carcinoma[J]. Curr Oncol, 2023, 30( 2): 1818- 1830. DOI: 10.3390/curroncol30020141.
    [16]
    Zhang M H, Huang X F, Zhang Y L, et al. Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration[J]. Gut Microbes, 2025, 17( 1): 2519706. DOI: 10.1080/19490976.2025.2519706.
    [17]
    Zheng R P, Wang G Q, Pang Z Q, et al. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma[J]. Cancer Med, 2020, 9( 12): 4232- 4250. DOI: 10.1002/cam4.3045.
    [18]
    Li R X, Yi X Z, Yang J H, et al. Gut microbiome signatures in the progression of hepatitis B virus-induced liver disease[J]. Front Microbiol, 2022, 13: 916061. DOI: 10.3389/fmicb.2022.916061.
    [19]
    Lapidot Y, Amir A, Nosenko R, et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma[J]. mSystems, 2020, 5( 3): e00153-20. DOI: 10.1128/mSystems.00153-20.
    [20]
    Ma C, Yang J, Fu X N, et al. Microbial characteristics of gut microbiome dysbiosis in patients with chronic liver disease[J]. World J Hepatol, 2025, 17( 5): 106124. DOI: 10.4254/wjh.v17.i5.106124.
    [21]
    Jinato T, Anuntakarun S, Satthawiwat N, et al. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma[J]. Appl Microbiol Biotechnol, 2024, 108( 1): 34. DOI: 10.1007/s00253-023-12845-1.
    [22]
    Liu Q S, Li F, Zhuang Y Y, et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma[J]. Gut Pathog, 2019, 11: 1. DOI: 10.1186/s13099-018-0281-6.
    [23]
    Yan F N, Zhang Q, Shi K, et al. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response[J]. Front Cell Infect Microbiol, 2023, 13: 1152987. DOI: 10.3389/fcimb.2023.1152987.
    [24]
    Kim S J, Jung C W, Anh N H, et al. Metabolic phenotyping combined with transcriptomics metadata fortifies the diagnosis of early-stage Hepatocellular carcinoma[J]. J Adv Res, 2025, 74: 153- 163. DOI: 10.1016/j.jare.2024.09.007.
    [25]
    Che Y B, Chen G Y, Guo Q Q, et al. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis[J]. Hepatology, 2023, 78( 1): 88- 102. DOI: 10.1097/HEP.0000000000000047.
    [26]
    Behary J, Amorim N, Jiang X T, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun, 2021, 12( 1): 187. DOI: 10.1038/s41467-020-20422-7.
    [27]
    Yu Q, Dai W Q, Ji J, et al. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway[J]. J Cell Mol Med, 2022, 26( 10): 3031- 3045. DOI: 10.1111/jcmm.17322.
    [28]
    Wang H G, Huang X D, Shen P, et al. Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro[J]. Int J Mol Med, 2013, 31( 4): 967- 974. DOI: 10.3892/ijmm.2013.1285.
    [29]
    Sanaei M, Kavoosi F, Safari M. Effect of 5’-Fluoro-2’-Deoxycytidine and sodium butyrate on the gene expression of the intrinsic apoptotic pathway, p21, p27, and p53 genes expression, cell viability, and apoptosis in human hepatocellular carcinoma cell lines[J]. Adv Biomed Res, 2023, 12: 24. DOI: 10.4103/abr.abr_211_21.
    [30]
    Pant K, Yadav A K, Gupta P, et al. Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells[J]. Redox Biol, 2017, 12: 340- 349. DOI: 10.1016/j.redox.2017.03.006.
    [31]
    Pant K, Saraya A, Venugopal S K. Oxidative stress plays a key role in butyrate-mediated autophagy via Akt/mTOR pathway in hepatoma cells[J]. Chem Biol Interact, 2017, 273: 99- 106. DOI: 10.1016/j.cbi.2017.06.001.
    [32]
    Chang Q M, Mao H R, Feng J F, et al. Sodium butyrate increases USP5-mediated ubiquitination degradation of GPX4 and enhances anti-cancer efficacy of anti-PD-1 antibody[J]. Biochem Pharmacol, 2025, 237: 116927. DOI: 10.1016/j.bcp.2025.116927.
    [33]
    Shalhoub H, Gonzalez P, Dos Santos A, et al. Simultaneous activation and blockade of autophagy to fight hepatocellular carcinoma[J]. Autophagy Rep, 2024, 3( 1): 2326241. DOI: 10.1080/27694127.2024.2326241.
    [34]
    de Oliveira Andrade F, Furtado K S, Heidor R, et al. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis[J]. Carcinogenesis, 2019, 40( 8): 979- 988. DOI: 10.1093/carcin/bgy190.
    [35]
    Yamamoto K, Kuzuya T, Honda T, et al. Relationship between adverse events and microbiomes in advanced hepatocellular carcinoma patients treated with sorafenib[J]. Anticancer Res, 2020, 40( 2): 665- 676. DOI: 10.21873/anticanres.13996.
    [36]
    Inukai Y, Yamamoto K, Honda T, et al. Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma[J]. Dig Dis, 2023, 41( 1): 138- 147. DOI: 10.1159/000524298.
    [37]
    Ponziani F R, de Luca A, Picca A, et al. Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma[J]. Hepatol Commun, 2022, 6( 6): 1492- 1501. DOI: 10.1002/hep4.1905.
    [38]
    Lee P C, Wu C J, Hung Y W, et al. Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy[J]. Hepatology, 2025. DOI: 10.1097/HEP.0000000000001446.
    [39]
    Hashem H R, Yehia T, Azab M, et al. Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: A cross-sectional study[J]. Gut Pathog, 2025, 17( 1): 88. DOI: 10.1186/s13099-025-00761-w.
    [40]
    Zhao C B, Zhang Z L, Ding R L, et al. Genes modulating butyrate metabolism for assessing clinical prognosis and responses to systematic therapies in hepatocellular carcinoma[J]. Biomolecules, 2022, 13( 1): 52. DOI: 10.3390/biom13010052.
    [41]
    Jing G X, Xu W Q, Ma W, et al. Echinacea purpurea polysaccharide intervene in hepatocellular carcinoma via modulation of gut microbiota to inhibit TLR4/NF-κB pathway[J]. Int J Biol Macromol, 2024, 261( Pt 2): 129917. DOI: 10.1016/j.ijbiomac.2024.129917.
    [42]
    Shou J W, Shaw P C. Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J]. Phytomedicine, 2023, 115: 154842. DOI: 10.1016/j.phymed.2023.154842.
    [43]
    He Huaxing, Liu Lulin, Liu Yingyin, et al. Sodium butyrate and sorafenib synergistically inhibit hepatocellular carcinoma cells possibly by inducing ferroptosis through inhibiting YAP[J]. J South Med Univ, 2024, 44( 7): 1425- 1430. DOI: 10.12122/j.issn.1673-4254.2024.07.23.

    何华星, 刘璐琳, 刘颖茵, 等. 丁酸钠与索拉非尼可能通过YAP诱导铁死亡协同抑制肝癌细胞增殖[J]. 南方医科大学学报, 2024, 44( 7): 1425- 1430. DOI: 10.12122/j.issn.1673-4254.2024.07.23.
    [44]
    Kumar M, Kaur R, Kanthaje S, et al. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2023, 149( 9): 5823- 5839. DOI: 10.1007/s00432-022-04544-7.
    [45]
    Zhu X H, Li K, Liu G C, et al. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell[J]. Gut Microbes, 2023, 15( 2): 2249143. DOI: 10.1080/19490976.2023.2249143.
    [46]
    Pant K, Mishra A K, Pradhan S M, et al. Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1/Ac-p53 regulatory axis[J]. Mol Carcinog, 2019, 58( 4): 524- 532. DOI: 10.1002/mc.22946.
    [47]
    Zhang F F, Ekk Lo, Chen C J, et al. Probiotics mixture, prohep: A potential adjuvant for low-dose sorafenib in metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma suppression through modulating gut microbiota[J]. Probiotics Antimicrob Proteins, 2025. DOI: 10.1007/s12602-025-10593-4.
    [48]
    Nouso K, Shiota S, Fujita R, et al. Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab[J]. Cancer Med, 2023, 12( 17): 17849- 17855. DOI: 10.1002/cam4.6416.
    [49]
    Lu K, Dong S W, Wu X Y, et al. Probiotics in cancer[J]. Front Oncol, 2021, 11: 638148. DOI: 10.3389/fonc.2021.638148.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (67) PDF downloads(19) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return